Key Takeaway: Kura Oncology, a clinical-stage biopharmaceutical company, will participate in the Jefferies Global Healthcare Conference on November 19, 2025. The event will feature a live audio webcast available on the company's website. Kura is dedicated to developing precision medicines for cancer, including its drug candidate ziftomenib for acute myeloid leukemia.
Price reaction · baseline $10.68 (2025-11-12 close) · hit after-hours · 1 other KURA headline(s) in the window, move may be shared
day 0 close
0%
Conference Participation Details
Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat
How to Access
Investors and the general public can listen to both sessions live at:
Archived versions will be available following the live events for a limited time.
Market Sentiment Analysis
POSITIVE FACTORS
Kura Oncology is participating in a notable investor conference.
The company is focused on precision medicines for cancer treatment.
Kura has a promising pipeline targeting significant cancer pathways.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic
Full Press Release Details
SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conference:
Jefferies Global Healthcare ConferenceNovember 19, 20253:30 p.m. GMT / 10:30 a.m. ET / 7:30 a.m. PT
A live audio webcast will be available in the Investors section of Kura’s website athttps://kuraoncology.com/, with an archived replay available following the event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website athttps://kuraoncology.com/and follow us onXandLinkedIn.
Frequently Asked Questions
When is Kura Oncology's investor conference participation?
Kura Oncology will participate in the Jefferies Global Healthcare Conference on November 19, 2025.
Where can I watch the Kura Oncology conference webcast?
The live audio webcast will be available in the Investors section of Kura's website.
What is Kura Oncology focused on?
Kura Oncology is committed to developing precision medicines for cancer treatment.
What is ziftomenib?
Ziftomenib is a menin inhibitor targeting genetic drivers of acute myeloid leukemia.